Post Oak Group Identifies Middle Market as Key Growth Driver for 2026 MA US Funds Build Cash Reserves Ahead of Anticipated SpaceX and OpenAI Public Listings CRISPR Therapeutics Releases First Quarter 2026 Results Key Updates on Gene Editing Pipeline Prediction Markets Point to IonQ Micron Anduril as Next Potential US Government Stake Targets Spotify Shares Surge 13 on AI Music Deal with Universal Music and Ambitious 2030 Guidance AI Economy Reshapes Labor Market Skilled Trades Emerge as Winners Over College Graduates DTE Energy Q1 2026 Earnings EPS Misses Estimates by 387 Despite Positive Stock Response FLG Q1 2026 Earnings EPS beats estimates as Flagstar delivers positive surprise Cadrenal Therapeutics Q1 2026 Earnings Narrowed Loss Surpasses Estimates Stock Edges Higher VVX Q1 2026 Earnings EPS Surges Past Expectations as Operations Drive Strong Beat FORTY Q1 2025 Earnings EPS of 123 Reported Amid Stock Decline Immunic Q1 2026 Earnings EPS Miss but Stock Surges 6 as Clinical Progress May Lift Sentiment PayPay Corporation PAYP Surges 246 Testing Key Resistance After Strong Move Eaton Vance Municipal Income Trust EOT Edges Higher Support and Resistance Levels in Focus Telecom Argentina TEO Holds Steady Near Support Amidst Modest Decline Adobe Inc ADBE Holds Steady Near Resistance A Measured Advance Fulton Financial Preferred Stock FULTP Sees Minor Dip Holds Near Support Zone Locafy LCFY Declines Amid Volume Patterns Key Levels Under Scrutiny Viavi Solutions VIAV Rises 129 as Stock Approaches Key Resistance at 5209 Varonis Systems VRNS Holds Steady Amid Minor Dip Key Levels in Focus MBINM Holds Steady at 2575 Amid Low Volume as Preferred Shares Maintain Tight Range Air Lease Corporation Holds Steady at 6500 as Key Support and Resistance Levels Remain in Focus BlackRock Virginia Municipal Bond Trust BHV Holds Steady at 1133 Amidst Flat Trading Session Markets SixWeek Rally Highlights Divergent Stock Performance in Portfolio GGB Q1 2026 Earnings EPS Misses Estimates by 20 Shares Edge Higher on Steel Demand Optimism Kymera Therapeutics KYMR Holds Steady at 8136 as Investors Weigh Support and Resistance Levels